• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » COVID-19 test sales boost Abbott in Street-beating Q4

COVID-19 test sales boost Abbott in Street-beating Q4

January 27, 2021 By Sean Whooley

AbbottAbbott (NYSE:ABT) shares ticked up this morning on fourth-quarter results that bested the consensus forecast.

The Abbott Park, Ill.-based company posted profits of $2.2 billion, or $1.20 per share, on sales of $10.7 billion for the three months ended Dec. 31, 2020, for a more than doubled bottom line on sales growth of 28.7%.

Adjusted to exclude one-time items, earnings per share were $1.45, 10¢ ahead of Wall Street, where analysts were looking for sales of $9.94 billion.

Three of Abbott’s four major businesses (nutrition, diagnostics and medical devices) saw growth in the quarter, while the company’s established pharmaceuticals arm dipped by -2.3%.

Diagnostics, in particular, saw a huge leap year-over-year, with $2.4 billion in COVID-19 testing revenue boosting the segment to more than $4.3 billion in sales, marking a 111.1% growth from 2019. Abbott has delivered 400 million COVID-19 diagnostic tests since the pandemic began, including 300 million in Q4 2020 alone, CEO Robert Ford told analysts during a call this morning.

Abbott’s BinaxNow rapid antigen test and its international counterpart, the PanBio COVID-19 Ag rapid diagnostic, led the quarter in diagnostics sales, he noted. Abbott has increased the manufacturing of these two tests to 100 million per month.

“We realized very early that a variety of different testing solutions would be required to handle the pandemic,” Ford said. “COVID testing has been a big driver for us and will continue to be a big driver. I expect testing demand will remain high even as the vaccine rolls out. I don’t think  we’ve seen testing demand peak yet.”

Medical device sales were relatively flat, bringing in $3.3 billion for 1.7% growth, although U.S. sales dipped by -2.5%. Lower sales in cardiovascular and neuromodular devices were balanced out by a 30% jump in sales in the diabetes segment. Ford told analysts he expects medical procedure volumes to increase in late summer and fall 2021.

“Despite challenging conditions, we achieved double-digit EPS growth, delivered ground-breaking innovation and advanced our new product pipeline in 2020,” Ford said separately in a news release. “We exited the year with a lot of momentum and are forecasting EPS growth of more than 35% in 2021.”

Abbott said it now expects to log adjusted EPS of at least $5 for full-year 2021, with its diluted EPS expected to be at least $3.74.

Ford has high hopes for the company’s recently cleared handheld rapid test for concussions, which operates on its i-STAT Alinity platform, testing the patient’s plasma to provide results within 15 minutes. Abbott is also seeking FDA breakthrough device designation for a whole-blood point-of-care concussion test, which the company would market to 25,000 high schools and 5,000 colleges, he noted. “I see that as a great opportunity,” Ford said.

Abbott will focus on organic growth rather than mergers and acquisitions in 2021, the CEO added. That will include the Q1 international launch of the Freestyle Libre 3 continuous glucose monitor, which gained the CE Mark in September 2020, and the U.S. launch of the product pending FDA approval.

ABT shares were slightly up, rising 0.1% at $114.83 per share in early-morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -1.9%.

Medical Design & Outsourcing managing editor Nancy Crotti contributed to this report.

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Abbott, coronavirus, COVID-19

In case you missed it

  • Organ-chips could streamline drug development, but hurdles remain
  • Ivermectin not supported for mild COVID-19, study says
  • ControlRad gains clearance for imaging tech to sell to Boston Sci
  • Capsule lands Frost & Sullivan award for remote ventilator monitor
  • Philips debuts AI-enhanced imaging platform
  • Pulmatrix completes $40M offering, updates product pipeline timetable
  • Medtronic launches IDE trial for AFib tech
  • Medtronic hiring Walmart exec to run its supply chain
  • An Overview of IEC 60601-1 3rd Edition, 2nd Amendment
  • Report: Permira eyeing LivaNova purchase
  • Amgen to acquire Five Prime Therapeutics for $1.9B
  • Medtronic wins city council approval for 42-acre campus in Colorado
  • Conformis dips 9% on Street-beating Q4 results
  • Becton Dickinson acquires smart medication device maker GSL Solutions
  • FDA clears once-daily ADHD capsule from Corium
  • Philips and Disney want to make MRIs easier for children: Here’s how
  • Origami Surgical gains FDA clearance for robotic suturing devices

RSS From Medical Design & Outsourcing

  • Medtronic hiring Walmart exec to run its supply chain
    Medtronic (NYSE:MDT) CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain. In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of… […]
  • Philips and Disney want to make MRIs easier for children: Here’s how
    Royal Philips (NYSE:PHG) announced today that it is teaming up with Disney to test the effects of custom-made animation to create a relaxing atmosphere for young patients. Amsterdam-based Philips will collaborate with The Walt Disney Company EMEA to see whether the animation, including specially-made Disney stories within Philips’ Ambient Experience, creates a relaxing atmosphere to improve… […]
  • Origami Surgical gains FDA clearance for robotic suturing devices
    Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform. The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic… […]
  • NAMSA acquires American Preclinical
    Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January. The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs,… […]
  • 5 reasons Medtronic’s CEO is optimistic about the future
    Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming. In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more. Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are… […]
  • Medtronic is changing a lot: Here’s what you need to know
    CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere. In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s… […]
  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
    Frost & Sullivan today announced that it awarded Ambu with a 2021 Global New Product Innovation Award. Ambu received the award for its single-use flexible endoscopes that are designed to make the devices safe, affordable and accessible. It has aView and aBox all-in-one video displays that eliminate the traditional video endoscopy tower size and expense to be… […]
  • Could this hydrogel repair a broken heart?
    European researchers have developed an injectable hydrogel that could help repair and prevent further heart muscle damage after a heart attack. The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodeling following a heart attack,… […]
  • How EtO plants can avoid lawsuits, cope with stricter regulation
    If EtO industry actors take certain targeted steps now, they can minimize legal exposure, more efficiently manage litigation and be better situated for compliance once new federal regulations are established. Karen Cullinane, Goldberg Segalla The use of ethylene oxide (EtO) to sterilize medical devices came under renewed scrutiny after the Environmental Protection Agency concluded in… […]
  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS